Table 2 Clinical characteristics of our population.

From: Simulation of atherosclerotic plaque growth using computational biomechanics and patient-specific data

 

All patients (N = 94)

Age at follow-up (years)

60.30 ± 8.54

Interscan period (years)

6.11 ± 1.34

Gender (male)

57 (60.64%)

Current smoker

13 (13.83%)

Family history of CAD

49 (52.13%)

Co-morbidities

Diabetes mellitus

14 (14.89%)

Hypertension

116 (58.29%)

Dyslipidemia

68 (72.34%)

Obesity

20 (21.28%)

Biochemical

Triglycerides mg/dL

113.81 ± 62.92

Total cholesterol mg/dL

185.55 ± 45.63

LDL mg/dL

108.16 ± 38.08

HDL mg/dL

55.96 ± 15.51

Medications at discharge

Aspirin

51 (54.26%)

ARB

13 (13.83%)

Beta-blocker

37 (39.36%)

ACE inhibitors

23 (24.47%)

Statin

44 (46.81%)

Stenosis at baseline

No stenosis

17 (18.09%)

< 30%

17 (36.17%)

30–50%

21 (22.34%)

50–70%

13 (13.83%)

70–90%

6 (6.38%)

> 90%

3 (3.19%)

  1. LDL low density lipoprotein, HDL high density lipoprotein, ARB Angiotensin II Receptor Blockers, ACE Angiotensin-converting enzyme.
Back to article page